In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: NeoGenomics trades below its PERT-weighted fair value ($11.35 vs. $15.57), indicating a 37.2% implied upside with high valuation confidence. However, the negative DCF mid-value contrasts sharply with strong Price/Sales and EV/Revenue metrics, suggesting cash flow challenges despite growth potential. Monte Carlo shows negligible downside risk, but profitability and efficiency scores at zero highlight operational vulnerabilities.